Related Experiment Video
Updated: Sep 7, 2025

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography
Published on: October 28, 2020
Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes
Andrea Salzano1, Roberta D'Assante2,3, Massimo Iacoviello4
1IRCCS SYNLAB SDN, Diagnostic and Nuclear Research Institute, Naples, Italy.
Insights
Patients with chronic heart failure (CHF) and type 2 diabetes (T2D) experience worse outcomes. T2D significantly worsens right ventricular function and exercise capacity in CHF patients over time.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Syndrome
Background:
- Patients with chronic heart failure (CHF) and impaired insulin axis (insulin resistance-IR or type 2 diabetes-T2D) show increased morbidity and mortality.
- Limited data exists on the distinct impacts of IR and T2D on cardiac structure, function, and cardiopulmonary performance in CHF patients.
Purpose of the Study:
- To investigate the differential effects of insulin resistance (IR) and type 2 diabetes (T2D) on cardiac structure and function in patients with chronic heart failure (CHF).
- To assess the impact of IR and T2D on cardiopulmonary performance and its longitudinal changes in CHF patients.
Main Methods:
- Utilized data from the T.O.S.CA. Registry, including echocardiography and cardiopulmonary exercise tests at baseline and follow-up (average 36 months).
- Classified patients into three groups: euglycemic without IR (EU), euglycemic with IR (IR), and T2D.
Main Results:
- T2D patients exhibited increased filling pressures (E/e'ratio) and worse right ventricular-arterial uncoupling (RVAUC) compared to EU and IR groups.
- Peak oxygen consumption (peak VO2) was significantly impaired in T2D patients versus EU and IR groups.
- Longitudinal analysis revealed greater deterioration in RVAUC, right ventricular dimensions, and peak VO2 in the T2D group.
Conclusions:
- The heightened risk of death and CV hospitalizations in CHF patients with T2D is linked to progressive right ventricular dysfunction and exercise impairment.
- Hyperglycemia and right heart chamber status are critical factors influencing prognosis in heart failure patients.
Background:
Findings from the T.O.S.CA. Registry recently reported that patients with concomitant chronic heart failure (CHF) and impairment of insulin axis (either insulin resistance-IR or diabetes mellitus-T2D) display increased morbidity and mortality. However, little information is available on the relative impact of IR and T2D on cardiac structure and function, cardiopulmonary performance, and their longitudinal changes in CHF.
Methods:
Patients enrolled in the T.O.S.CA. Registry performed echocardiography and cardiopulmonary exercise test at baseline and at a patient-average follow-up of 36 months. Patients were divided into three groups based on the degree of insulin impairment: euglycemic without IR (EU), euglycemic with IR (IR), and T2D.
Results:
Compared with EU and IR, T2D was associated with increased filling pressures (E/e'ratio: 15.9 ± 8.9, 12.0 ± 6.5, and 14.5 ± 8.1 respectively, p < 0.01) and worse right ventricular(RV)-arterial uncoupling (RVAUC) (TAPSE/PASP ratio 0.52 ± 0.2, 0.6 ± 0.3, and 0.6 ± 0.3 in T2D, EU and IR, respectively, p < 0.05). Likewise, impairment in peak oxygen consumption (peak VO2) in TD2 vs EU and IR patients was recorded (respectively, 15.8 ± 3.8 ml/Kg/min, 18.4 ± 4.3 ml/Kg/min and 16.5 ± 4.3 ml/Kg/min, p < 0.003). Longitudinal data demonstrated higher deterioration of RVAUC, RV dimension, and peak VO2 in the T2D group (+ 13% increase in RV dimension, - 21% decline in TAPSE/PAPS ratio and - 20% decrease in peak VO2).
Conclusion:
The higher risk of death and CV hospitalizations exhibited by HF-T2D patients in the T.O.S.CA. Registry is associated with progressive RV ventricular dysfunction and exercise impairment when compared to euglycemic CHF patients, supporting the pivotal importance of hyperglycaemia and right chambers in HF prognosis. Trial registration ClinicalTrials.gov identifier: NCT023358017.
Related Concept Videos
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure IV: Classification and Diagnostic Evaluation

